I. CALL TO ORDER
The meeting of the Benefits Committee was called to order at 9:00 a.m. by Trustee Laurel Johnston, Chairperson, in the Hawaii Employer-Union Health Benefits Trust Fund (EUTF) Conference Room, 201 Merchant Street, Suite 1700, Honolulu, Hawaii, on Tuesday, May 18, 2021.

II. MINUTES – April 20, 2021
The Benefits Committee reviewed the draft minutes of April 20, 2021.

MOTION was made and seconded to approve the minutes of April 20, 2021, as circulated. (Tui/Fern) The motion passed unanimously. (Employer Trustees-2/Employee-Beneficiary Trustees-2)
III. NEW BUSINESS

A. Proposed retiree plan changes effective January 1, 2022
   Mr. Troy Tomita, Kaiser Permanente, presented a memorandum regarding 2022 Retiree Benefit Change, dated May 18, 2021 noting Kaiser’s recommendation to remove coverage limitations on treatment of chemical dependency in a nonhospital residential facility under the EUTF and HSTA VB Kaiser Permanente Senior Advantage (KPSA) medical and prescription drug plans effective January 1, 2022. Mr. Tomita noted no other Kaiser plans, including other EUTF and HSTA VB Kaiser plans, have such limitations and referred the Committee to the memorandum in terms of the impact on the premiums and incidence rate for the EUTF and HSTA VB KPSA plans.

MOTION was made and seconded to recommend to the Board removal of coverage limitations on treatment of chemical dependency in a nonhospital residential facility under the EUTF and HSTA VB Kaiser Permanente Senior Advantage medical and prescription drug plans effective January 1, 2022. (Tui/Fern) The motion passed unanimously. (Employer Trustees-2/Employee-Beneficiary Trustees-3)

B. COVID-19 related plan changes
   Mr. Tomita presented a memorandum regarding COVID-19 treatment update, dated May 18, 2021 noting that the enhanced coverage at 100% of treatment related to a positive COVID-19 diagnosis will end July 31, 2021. Mr. Derek Mizuno noted that the Board had delegated the ending of this enhanced benefit to Kaiser at its April 28, 2020 Board meeting. Kaiser believes the enhanced coverage is no longer necessary as the COVID-19 vaccination is widely available to the general public.

Ms. Stacia Baek, HMSA, presented a memorandum regarding Cost-share waiver for treatment of adverse reaction to COVID-19 vaccine and extension of previously approved COVID-19 related benefit cost share waivers, dated May 18, 2021 noting HMSA’s recommendation to provide enhanced coverage at 100% for treatment of adverse reactions to the COVID-19 vaccine. HMSA is making this change for their book of business to remove any barriers to receiving the COVID-19 vaccine. Ms. Baek noted the minimal cost impact due to the low incidence in EUTF and HMSA book of business plans.

MOTION was made and seconded to recommend to the Board waiver of member cost share for treatment of adverse reactions to the COVID-19 vaccine retroactive to December 1, 2020 through the end of the public health emergency under the EUTF and HSTA VB HMSA active employee and retiree medical plans. (Tui/Fern) The motion passed unanimously. (Employer Trustees-2/Employee-Beneficiary Trustees-3)

C. Segal capstone report: Turnkey program solutions to its cost driver analysis
   Mr. Steve Murphy, Segal Consulting, summarized the EUTF Health Plan Cost Analysis, Capstone Report noting the following:

   1. The cost drivers are diabetes, cardiovascular conditions, oncology and musculoskeletal disorders.
2. Recommended programs focus on HMSA and CVS programs as Kaiser has been able to control disease as measured by Healthcare Effectiveness Data and Information Set (HEDIS) measures.

3. Recommended programs are CVS Accordant Care Rare through HMSA, CVS Accordant Care Specialty Pharmacy Management, CVS Pharmacy Advisor Counseling, and either Livongo’s Diabetes Management Program or Whole Person Health Program through HMSA. The Whole Person Health Program targets multiple EUTF key cost drivers including: pre-diabetes, diabetes, and high blood pressure.

Trustee Ferguson-Miyamoto entered the meeting at 9:45 a.m.

IV. NEXT MEETING DATE – July 20, 2021
Next meeting agenda to include CVS prescription drug plan changes and the Strategic Plan (7/1/21-6/30/25).

V. ADJOURNMENT
MOTION was made and seconded to adjourn the meeting at 9:51 a.m. (Tui/Fern) The motion passed unanimously. (Employer Trustees-2/Employee-Beneficiary Trustees-4)

Respectfully submitted,

/s/
Laurel Johnston, Chairperson

APPROVED on July 20, 2021.

Documents Distributed:
1. Draft Benefits Committee Minutes of April 20, 2021. (2 pages)
3. Memorandum to BOT from Kaiser Permanente, regarding 2022 Retiree Benefit Change, dated May 18, 2021, redacted version. (1 page)
4. Memorandum to BOT from Kaiser Permanente, regarding COVID19 treatment update, dated May 18, 2021. (1 page)
5. Memorandum to BOT from HMSA, regarding Cost-share waiver for treatment of adverse reaction to COVID-19 vaccine and extension of previously approved COVID-19 related benefit cost share waivers, dated May 18, 2021. (2 pages)